Professor Jacqui Shaw

Professor Shaw is Head of the Department of Genetics and Genome Biology, Co-Director of the Leicester Precision Medicine Institute and Professor of Translational Cancer Genetics at the University of Leicester. Her extensive expertise in innovative blood-based tests for monitoring breast and lung cancers, known as liquid biopsies, is highly sought after through national and international collaborations in clinical studies and trials.

Professor Shaw’s research has found that breast cancer recurrence can be detected by a blood test up to two years ahead of when traditional screening techniques would be able to detect it. This highly impactful work enabled US-based genetic testing company Natera achieve the prestigious 'Breakthrough Device' designation from the U.S. Food and Drug Administration (FDA) in 2019 for their Signatera™ test, which offers patients personalised cancer testing.

Professor Shaw’s research group’s expertise is in molecular diagnostics. This expertise was deployed during the coronavirus pandemic to establish and lead on asymptomatic screening for COVID-19 at the University of Leicester, using a quick antigen test known as LAMP - Loop-mediated isothermal amplification. This screening programme has supported the University in the early detection of COVID-19 outbreaks on campus by detecting staff and students with asymptomatic cases who may have unknowingly spread the virus.